Home › Compare › CDGLY vs ABBV
CDGLY yields 5.05% · ABBV yields 3.06%● Live data
📍 CDGLY pulled ahead of the other in Year 2
Combined, CDGLY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CDGLY + ABBV for your $10,000?
ComfortDelGro Corporation Limited, an investment holding company, provides public transport services in Singapore. It operates through seven segments: Public Transport Services, Taxi, Automotive Engineering Services, Inspection and Testing Services, Driving Centre, Car Rental and Leasing, and Bus Station. The company offers bus and rail services to commuters; taxi and coach rental, and related advertisement services; non-emergency transport services to patients; vehicular maintenance and repair services; assembly of bus bodies; crash repair services; and engineering services, as well as sells diesel and petrol. It is also involved in the provision of motor vehicle inspection, non-vehicle testing, inspection, and consultancy services; construction of specialized vehicles; operation of taxi bureau, scheduled services, and driving schools; electric vehicle charging infrastructure activities; and renting and leasing of cars. In addition, the company offers public taxi and charter bus, management of taxi booking, building inspection, technology, and terminal services; and operates workshops for repairing, servicing, and general maintenance of motor vehicles. Further, it provides insurance broking, risk management, claims management, and related services; medical escort services; charge card facilities; and accident and other repair and maintenance services. As of March 30, 2022, the company operated a fleet of 35,000 buses, taxis, and rental vehicles. It also operates in the United Kingdom, Ireland, Australia, China, New Zealand, and Malaysia. ComfortDelGro Corporation Limited was incorporated in 2003 and is headquartered in Singapore.
Full CDGLY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.